Pionyr Maps Tumor Microenvironment, Plans 'Surgical' Strikes

 
• By Emily Hayes

Emerging Company Profile: Pionyr Immunotherapeutics exec who once led early development for Merck's PD-1 inhibitor Keytruda explains the San Francisco start-up's approach to rebalancing the tumor's microenvironment in order to improve outcomes.

Emerging Company Profile Regular column feature image Version 2

More from Start-Ups & SMEs

More from Business